Drug intelligence / Profile preview

AST-914

Development stage: Preclinical
Lead developer: Novartis
Modality: Small Molecules
Administration: Subcutaneous

Overview

AST-914 is a product candidate that originated from Ariston Pharmaceuticals, which was acquired by Manhattan Pharmaceuticals, Inc. through a merger. It is specifically referred to as an "AST-914 metabolite product candidate," suggesting it is either a metabolite being developed as a drug or a drug derived from a metabolite. The development of AST-914 was tied to specific product-related milestones within the merger agreement between Manhattan Pharmaceuticals and Ariston Pharmaceuticals. Further details regarding its mechanism of action or primary indication are not available in the provided information.

Targets

CaSR (Extracellular calcium-sensing receptor)

Beyond the preview

Go deeper on AST-914.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AST-914.

Explore the full profile